Introduction
Bisphosphonates (BP) are powerful bone resorption inhibitors. They are used for the symptomatic treatment of malignant osteolytic bone disease (e.g., multiple myeloma and bone metastasis), as well as bone diseases associated with high bone resorption (e.g., postmenopausal osteoporosis, cortisone-induced osteoporosis). However, recent data showed that a rare, but serious, adverse effect of BP therapy is bisphosphonate related osteonecrosis of the jaw (BRONJ). Given the increasing number of persons receiving chronic oral-BP therapy, it is important to accurately identify pathogenesis, risk factors and management strategies for BRONJ in patients with non-malignant disease. The objective of this study was to review cases of BRONJ occurring in association with benign disease and to describe and compare the clinical course and outcome for patients with BRONJ and rheumatoid arthritis or osteoporosis.
We retrospectively reviewed observations of all patients referred for treatment and follow-up for BRONJ from January 2007 to December 2011. Demographic data, medical history, maxillofacial findings, BRONJ treatment and follow-up were reviewed for each case. Over a five-year period, we diagnosed 112 patients with BRONJ. Among these patients, 15 received bisphosphonate treatment for non-malignant disease.
Conclusion
Comparative analysis of all the variables showed no statistically significant differences between patients with rheumatoid arthritis and others. However, our study is the first, to our knowledge, to distinguish and compare 2 groups of patients treated with BP for non malignant disease. In conclusion, within the limits of our study (small size cohort, lack of control group, patients referred to our department for ONJ), our results suggest that RA does not alter the BRONJ disease spectrum, clinical course or outcome. Further studies are needed to assess the incidence and prevalence of osteonecrosis of the jaws in patients with RA. 
At risk category
No apparent exposed/necrotic bone in patients who have been treated with either oral or IV bisphosphonates
Stage 0
Nonspecific clinical findings and symptoms such as jaw pain or osteosclerosis but no clinical evidence of exposed bone Stage 1 Exposed/necrotic bone in patients who are asymptomatic and have no evidence of infection.
Stage 2
Exposed/necrotic bone associated with infection as evidenced by pain and erythema in the region of the exposed bone with or without purulent drainage
Stage 3
Exposed/necrotic bone in patients with pain, infection, and one or more of the following: pathologic fracture, extra-oral fistula, or osteolysis extending to the inferior border or sinus floor A B
